The Bridge has an end date. Plan for it now.

The program runs through December 31, 2027 — "Bridge" is a candid name. That's not a reason to avoid it; it's a reason to start the long-term conversation with your doctor on day one, while the copay works in your favor.

Why this matters more for GLP-1s than most drugs

GLP-1 therapy is usually long-term — stopping often means regaining weight. So an eighteen-month coverage window raises a fair question: what happens in January 2028? The honest answer is that nobody knows yet. Medicare policy on weight-loss drugs could be extended, made permanent, or allowed to lapse. What you can control is having a plan for each possibility.

What might come next: the BALANCE model

There is a proposed successor, though nothing is settled. CMS has put forward the BALANCE model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) — a voluntary program that would pair GLP-1 access with lifestyle support, with CMS negotiating drug prices on behalf of plans. For Medicare, though, CMS delayed the Part D portion in April 2026, so whether it launches for Medicare in 2028 — to pick up where the Bridge leaves off — is still uncertain.

One difference worth knowing if it does arrive: unlike the Bridge, which runs outside your Part D plan, BALANCE would work through your Part D plan — your plan would handle the claim and prior authorization like any other covered drug. For now it's a possibility to watch, not a guarantee. We'll update this page as CMS finalizes details; always confirm against the current CMS BALANCE model materials.

Five questions to ask your doctor at the first visit

• If the Bridge ends and nothing replaces it, what are my options — Part D coverage for another indication, self-pay, a lower-cost alternative, or a maintenance plan?
• How will we measure whether the medication is working well enough to justify continuing, whatever the price?
• What should we document now — starting BMI, diagnoses, response to therapy — so any future coverage process has what it needs?
• How often will we reassess side effects, dose, and safety?
• If I had to stop, what would a safe off-ramp look like?

The optimistic read

Demonstrations exist to generate evidence. If the Bridge shows that covering GLP-1s for weight management improves health without runaway costs, that strengthens the case for permanent coverage. People who enroll, follow through, and document their outcomes are — in a small way — part of that case.

Either way, the practical move is the same: if you may fit the criteria, have the conversation early. More months in the program means more benefit from the copay and more data about how the medication works for you before any decision point arrives.

Build your record while the window is open

Whatever happens in 2028, a documented history helps. Ask your clinician to keep a clear record of your starting BMI, the conditions that put you on a criteria pathway, your dose, and how you've responded — weight, blood pressure, blood sugar, energy. If coverage shifts to a different route later (a Part D indication, a future program, or a manufacturer assistance option), that paper trail is exactly what a new approval process will look for. Starting early doesn't just save money now; it stacks the deck for continuity later.

Sources and review status: Content reviewed June 27, 2026, based on published CMS materials including the prescriber fact sheet (CMS Product No. 12235). Check current CMS materials: CMS Bridge overview, beneficiary fact sheet (PDF), provider information.